Stock Ratings / Health Care / AMRN / financials

QTTB (61) ABEO (39) IMRX (45) BCYC (24) ⌘ Pro Terminal →

Amarin Corporation plc (AMRN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$12.74 -0.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.71

Amarin Corporation plc (AMRN) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $262.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.71 (-0.20%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMRN)Realized 20D OHLCV Swing Band: ±7.4%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY AMRN SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (21% of score)

20D Institutional Volume Accumulation (±7.4% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk6/20 pts (-14 pt drag)

Balance-sheet & 10-K footnote risk deducts 14 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.03-5.9% Next Q

Q2 (-2Q)

Grade E$11.32+4.2% Next Q

Q3 (-1Q)

Grade D$11.79+8.1% Next Q

Current

Grade D-$12.74-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMRN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMRN currently carries a cautious 43/100 (D-) rating due to SEC 10-K Forensic Risk (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.97) and Max Pain ($13.38) forces dealer call-delta covering toward $18.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AMRN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$6.7M (3.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $306.9M

FY24

Rev $228.6M

FY25

Rev $213.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$213.6M	56.6%	-23.5%	-$38.8M	$6.7M	-12.2%
FY 2024	$228.6M	35.6%	-40.2%	-$87.0M	-$31.0M	-19.9%
FY 2023	$306.9M	56.6%	-22%	-$55.0M	$6.9M	-12.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMRN)

✓Walkthrough of AMRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.54%⚡ TESTING RESISTANCE

2026-10-30O $12.71H $12.76L $12.00C $12.74VOL 101.3K

RES: $13.25SUP: $10.87SMA50: $12.97SMA200: $14.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMRN Butterfly Map → + Track AMRN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRN)

Health Care Rank #547 of 1016 ⚔️ QTTB vs AMRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMRN vs. QTTB, ABEO, IMRX, BCYC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amarin Corporation plc (AMRN) ranks #547 by composite RQD confidence (43/100, grade D-) and #538 by equity capitalization ($262.8M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AMRN at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMRN ACTIVE Amarin Corporation plc	D-	43/100	—	56.6%	-12.2%	-0.08%	$262.8M	Benchmark Subject
QTTB Q32 Bio Inc.	C-	61/100	8.9x	—	85.0%	-2.10%	$264.1M	/qttb-vs-amrn →
ABEO Abeona Therapeutics Inc.	D-	39/100	—	73.7%	-35.0%	+0.22%	$260.8M	/abeo-vs-amrn →
IMRX Immuneering Corporation (Class A)	D	45/100	—	—	-35.0%	+0.75%	$260.1M	/imrx-vs-amrn →
BCYC Bicycle Therapeutics plc	E	24/100	—	—	-35.0%	-1.55%	$267.4M	/bcyc-vs-amrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000897448

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amarin Corporation plc (AMRN) reported GAAP revenue of $213.6M (-6.5% vs. FY2024 revenue of $228.6M , and -30.4% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of $6.7M, and free cash flow of $6.7M (+121.7% YoY). On the balance sheet, AMRN closed FY2025 with $670.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$213.6M	-$38.8M	$6.7M	$6.7M	$670.8M	—
FY2024 (FY)	2024-12-31	$228.6M	-$87.0M	-$31.0M	-$31.0M	$685.3M	—
FY2023 (FY)	2023-12-31	$306.9M	-$55.0M	$6.9M	$6.9M	—	—

3. AMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Amarin Corporation plc (NASDAQ: AMRN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $12.74 (-0.08% 1D, market cap $262.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, AMRN ranks #547 in composite RQD confidence.

How does AMRN compare to QTTB and ABEO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, QTTB (Q32 Bio Inc.) holds a C- grade (61/100 RQD, P/E 8.9x, ROIC 85.0%, cap $264.1M) and ABEO (Abeona Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMRN?

Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMRN last traded at $12.74 (-0.08% on volume of 40,045 shares), positioning the stock -1.77% below its 50-day simple moving average ($12.97) and -10.97% below its 200-day simple moving average ($14.31). Across its 52-week range of $11.25 to $17.31, AMRN sits at the 24.6% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($11.80 to $13.68).